Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).

ABSTRACT:

Background and purpose

Prompt thrombolytic therapy with intravenous alteplase reduces disability after acute ischemic stroke. In an exploratory analysis, we examined whether long-term survival varied by baseline characteristics after alteplase.

Methods

In this open-treatment, international, randomized, controlled trial, ischemic stroke patients were randomly allocated <6 hours of onset to intravenous alteplase (0.9 mg/kg) plus standard care (n=1515) or standard care alone (n=1520). We followed patients to death, censoring when last known to be alive. We grouped patients by delay to randomization, and good or poor predicted prognosis (calculated from baseline National Institutes of Health Stroke Scale [NIHSS] score and age). We present absolute mortality differences between t

SUBMITTER: Whiteley WN 

PROVIDER: S-EPMC4282176 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature